Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

<p>List of recurrent mutations with potential utility as neoantigens</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Lijun Yao (15292963) (author)
Diğer Yazarlar:	Julia T. Wang (15292966) (author), Reyka G. Jayasinghe (15131798) (author), Julie O'Neal (15292969) (author), Chia-Feng Tsai (15292972) (author), Michael P. Rettig (15292975) (author), Yizhe Song (15292978) (author), Ruiyang Liu (15292981) (author), Yanyan Zhao (15292984) (author), Omar M. Ibrahim (15292987) (author), Mark A. Fiala (15032471) (author), Julie M. Fortier (15292990) (author), Siqi Chen (15292993) (author), Leah Gehrs (15292996) (author), Fernanda Martins Rodrigues (15292999) (author), Michael C. Wendl (15293002) (author), Daniel Kohnen (15293005) (author), Andrew Shinkle (15293008) (author), Song Cao (15293011) (author), Steven M. Foltz (15293014) (author), Daniel Cui Zhou (15293017) (author), Erik Storrs (15293020) (author), Matthew A. Wyczalkowski (15293023) (author), Smrithi Mani (15293026) (author), Scott R. Goldsmith (15293029) (author), Ying Zhu (15293032) (author), Mark Hamilton (15131831) (author), Tao Liu (15293035) (author), Feng Chen (15293038) (author), Ravi Vij (15293041) (author), Li Ding (15061726) (author), John F. DiPersio (15293044) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Immuno-oncology Methods and Technology Hematological Cancers Myelomas Immunotherapy Single Cell Technologies
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Yazar:: Lijun Yao (15292963)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Yazar:: Lijun Yao (15292963)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Yazar:: Lijun Yao (15292963)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Yazar:: Lijun Yao (15292963)
Baskı/Yayın Bilgisi: (2025)

Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Yazar:: Lijun Yao (15292963)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S5 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S1 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S10 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S11 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S12 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S2 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S3 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S4 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S6 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S7 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S8 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Spreadsheet S9 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Yazar:: Eileen M. Boyle (15015425)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Yazar:: Keiji Kurata (15055090)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Yazar:: Keiji Kurata (15055090)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Yazar:: Keiji Kurata (15055090)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 5 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
Yazar:: Yunlu Jia (2012017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
Yazar:: Yunlu Jia (2012017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
Yazar:: Yunlu Jia (2012017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 3 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
Yazar:: Yunlu Jia (2012017)
Baskı/Yayın Bilgisi: (2025)

Supplementary table 5 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
Yazar:: Wei Chen (15053713)
Baskı/Yayın Bilgisi: (2025)

Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
Yazar:: Wei Chen (15053713)
Baskı/Yayın Bilgisi: (2025)

Supplementary table 7 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
Yazar:: Wei Chen (15053713)
Baskı/Yayın Bilgisi: (2025)

Discovery and Characterization of Novel BLIMP‑1 Heterobifunctional Ligand-Directed Degraders
Yazar:: Bryan J. Simmons (22676881)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
Yazar:: Ti Wen (15130158)
Baskı/Yayın Bilgisi: (2025)

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
Yazar:: Kazuhito Suzuki (22688384)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
Yazar:: Yibin Dai (16374331)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
Yazar:: Yibin Dai (16374331)
Baskı/Yayın Bilgisi: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables S1-S11 from Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic <i>TP53</i>-Mutant Clonal Hematopoiesis
Yazar:: Rathana Kim (15135915)
Baskı/Yayın Bilgisi: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
Yazar:: Stéphane Fattori (15048281)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_bll3649b8ahk03oac71o4qnj08